PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTTORNEY'S DOCKET NUMBER ON/4-32587A/UOC

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 24 July 2002 (24.07.02) PCT/IB03/01984 23 May 2003 (23.05.03) TITLE OF INVENTION 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-(4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING MUTATED-RET KINASE ASSOCIATED DISEASES APPLICANT(S) FOR DO/EO/US JAMES ALEXANDER FAGIN Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. X has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 10. 🔲 Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. 🗶 A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. A substitute specification. 16. 🗀 A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. 📖 A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. L A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

Other items or information: Unexecuted Declaration and Power of Attorney This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

FILING BY "EXPRESS MAIL" **UNDER 37 CFR 1.10**

EV4437884054S

Express Mail Label Number

Date of Deposit

20.

;

	er the Paperwork R	Act of 1995,	, no persons are required to respo	U.S	Patent and	oproved for use through 3. mark Office; U.S. DEPAR Ition unless it displays a second control of the control of	/31/200 RTMEN	IT OF COA	651- 0021 JMERCE
U.S. APPLICAT	HONNO Aiffmon	ON/4-325	OKE	2005					
21. The followi	011, 7 020	$\frac{277}{1}$,,,,,,						
a) Basic na	\$ 300.00	十							
b) Examina	\$ 200.00	十							
c) Search f	\$ 500.00	┰							
.,		\dashv							
Additional fe	\$ 1,000.00	1							
listing or cor additional 5	1	- [VALHE					
					LIBATIA				
Total Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)				RATE			DEPOSA	
- 100 =	/50 =							19	01
			0		x \$250.00	\$ 0.00		PEE	VAL
Surcharge of \$13	\$ 0.00		0001	FGPV					
claimed priority date (37 CFR 1.492(e)). CLAIMS NUMBER FILED NUMBER FXTRA RATE							Щ	1033	ردي
Total claims	10 - 20 =		NUMBER EXTRA	RATE		\$	\dashv		
			0	×		\$ 0.00		1/2/1	111
Independent clair	ENDENT CLAIM(S) (if ap	3 - 3 =	0	×	\$200.00 \$360.00	\$ 0.00	Ш	109	<u> </u>
MOLTIPLE DEPE	\$ 0.00	\perp							
TOTAL OF ABOVE CALCULATIONS = Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced						\$ 1,000.00			
by ½.						\$			
SUBTOTAL =						\$ 1,000.00		-	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$			
	\$ 1,000.00			$\neg \neg$					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$									
### ##################################									
	00058 <u>∽198154 105</u>) <i>A</i> [t R ount to be	unt to be							
02 FC:1632 500.0						refunded:	\$		
<u> </u>						Amount to be charged:	\$		
a. A check in the amount of \$ to cover the above fees is enclosed.									
b. Please charge my Deposit Account No. 19-0134 in the amount of \$ 1,000,00 to cover the above fees. A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 19-0134 . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this representation of the repres									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.									
SEND ALL CORR		,							
Novartis SIGNATURE						a xaet	<u> </u>		
_	ackson								
Corporate Intellectual Property One Health Plaza Plda 104						UCK3011			

One Health Plaza, Bldg. 104

East Hanover, NJ 07936-1080

48,152 REGISTRATION NUMBER